MAP moves closer with first inhaled migraine drug
This article was originally published in Scrip
Executive Summary
MAP Pharmaceuticals took another step closer this week to having the first inhaled migraine drug on the US market after completing its 12-month open-label, safety extension study. This is the final trial needed to support the company’s new drug application (NDA) for Levadex, whose active ingredient, dihydroergotamine (DHE), has been marketed for several decades.